

# **DANIEL L. HERTZ, PHARM.D, PHD**

[DLHertz@med.umich.edu](mailto:DLHertz@med.umich.edu)

## **PRESENT POSITION**

Assistant Professor  
Department of Clinical Pharmacy  
University of Michigan College of Pharmacy  
428 Church Street  
Ann Arbor, MI 48109  
Office: (734) 763-0015  
Fax: (734) 763-4480

## **EDUCATION AND TRAINING**

**SEPT 2008-** University of North Carolina at Chapel Hill  
**MAY 2013** UNC Eshelman School of Pharmacy  
Division of Pharmacotherapy and Experimental Therapeutics  
Chapel Hill, NC 27516  
Degree: Doctor of Philosophy (PhD) May 2013

**SEPT 2002-** Rutgers, The State University of New Jersey  
**MAY 2008** Ernest Mario School of Pharmacy  
Piscataway, NJ 08854  
Degree: Doctor of Pharmacy (PharmD) May 2008 (Summa Cum Laude)

**LICENSURE** New Jersey (License #28RI03227100, Active)  
North Carolina (License #20495, Inactive)

## **PROFESSIONAL EXPERIENCE AND ACADEMIC APPOINTMENTS**

**APRIL 2016-** Assistant Professor  
**PRESENT** Department of Clinical Pharmacy  
University of Michigan College of Pharmacy  
Ann Arbor, Michigan

**FEB 2014-** Affiliate Member, University of Michigan Rogel Cancer Center  
**PRESENT**

**APRIL 2013-** Research Assistant Professor  
**APRIL 2016** Department of Clinical Pharmacy  
University of Michigan College of Pharmacy  
Ann Arbor, Michigan

## **PUBLICATIONS**

### **PEER-REVIEWED PUBLICATIONS:**

1. **Hertz DL**, Smith KL, Zong Y, Gersch CL, Pesch AM, Lehman J, Blackford AL, Henry NL, Kidwell KM, Rae JM, Stearns V. Further evidence that OPG rs2073618 is associated with increased risk of musculoskeletal symptoms in patients receiving aromatase inhibitors for early breast cancer. *Frontiers in Genetics* 2021 (In Press)  
Role: Conceptualization, Writing, Corresponding Author
2. Chen CS<sup>^</sup>, Kim J\*, Garg N<sup>^^</sup>, Guntupalli H\*, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan B, **Hertz DL**. Chemotherapy-induced peripheral neuropathy detection via smartphone app: a cross-sectional pilot study. *JMIR mHealth and uHealth* 2021

Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author

3. Shakeel F<sup>^</sup>, Fang F, Kwon JW\*, Koo K\*, Pasternak AL, Henry NL, Sahai V, Kidwell KM, **Hertz DL**. [Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy](#). *Pharmacogenomics*. 2021 Feb;22(3):145-155. doi: 10.2217/pgs-2020-0154. Epub 2021 Jan 7. PubMed PMID: 33410339.  
Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author
4. Marcath LA<sup>^</sup>, Finley C\*, Wong SF, **Hertz DL**. [Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy](#). *BMC Cancer*. 2021 Mar 26;21(1):324. doi: 10.1186/s12885-021-08050-w. PubMed PMID: 33771105; PubMed Central PMCID: PMC7995697.  
Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author
5. Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, **Hertz DL**, Gersch CL, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. [Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer](#). *Oral Dis*. 2020 Dec 4; doi: 10.1111/odi.13746. [Epub ahead of print] PubMed PMID: 33274559.  
Role: Analysis Design, Writing, Critical Review
6. Helland T<sup>^</sup>, Naume B, Hustad S, Bifulco E, Kvaløy JT, Sætersdal AB, Synnøstvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, **Hertz DL**, Janssen EAM, Mellgren G, Søiland H. [Low Z-4OHTam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen](#). *Mol Oncol*. 2021 Apr;15(4):957-967. doi: 10.1002/1878-0261.12865. Epub 2020 Dec 14. PubMed PMID: 33252186; PubMed Central PMCID: PMC8024735.  
Role: Critical Review
7. Akhtari FS, Havener TM, **Hertz DL**, Ash J, Larson A, Carey LA, McLeod HL, Motsinger-Reif AA. [Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines](#). *Pharmacogenet Genomics*. 2021 Feb 1;31(2):48-52. doi: 10.1097/FPC.0000000000000419. PubMed PMID: 32941389.  
Role: Data Collection, Critical Review
8. **Hertz DL**, Douglas JA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. [Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity](#). *Pharmacogenetics and Genomics*: February 18, 2021 - Publish Ahead of Print doi: 10.1097/FPC.0000000000000429  
Role: Conceptualization, Analysis Design, Writing, Critical Review, Corresponding Author
9. Marcath LA<sup>^</sup>, Coe TD\*, Shakeel F<sup>^</sup>, Reynolds E, Bayuk M, Haas S, Redman BG, Wong SF, **Hertz DL**. [Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility Screening](#). *J Patient Saf*. 2021 Jan 1;17(1):e28-e34. doi: 10.1097/PTS.0000000000000772. PubMed PMID: 33003175; PubMed Central PMCID: PMC7775319.  
Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author
10. Chen Y<sup>^^</sup>, Fang F, Kidwell KM, Vangipuram K\*, Marcath LA<sup>^</sup>, Gersch CL, Rae JM, Hayes DF, Smith EM, Henry NL, Beutler AS, **Hertz DL**. [Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy](#). *Pharmacogenomics*. 2020 Aug;21(12):841-851. doi: 10.2217/pgs-2020-0053. Epub 2020 Jul 23. PubMed PMID: 32700628; PubMed Central PMCID: PMC7444626.  
Role: Conceptualization, Analysis Design, Writing, Critical Review, Corresponding Author
11. Jennaro TS\*\*, Fang F, Kidwell KM, Smith EM, Vangipuram K\*, Burness M, Griggs JJ, Van Poznak C, Hayes DF, Henry NL, **Hertz DL**. [Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy](#). *Breast Cancer Res Treat*. 2020 Apr;180(3):707-714. doi: 10.1007/s10549-020-05584-8. Epub 2020 Mar 12. PubMed PMID: 32166478.  
Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author

12. Salgado TM, Liu J, Reed HL\*, Quinn CS\*, Syverson JG\*, Le-Rademacher J, Lopez CL, Beutler AS, Loprinzi CL, Vangipuram K, Smith EML, Henry NL, Farris KB, **Hertz DL**. [Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study](#). *Breast*. 2020 Jun;51:21-28. doi: 10.1016/j.breast.2020.02.011. Epub 2020 Mar 3. PubMed PMID: 32193049; PubMed Central PMCID: PMC7198332.  
Role: Conceptualization, Analysis Design, Critical Review
13. Shakeel F^, Fang F, Kidwell KM, Marcath LA^, **Hertz DL**. [Comparison of eight screening tools to detect interactions between herbal supplements and oncology agents](#). *J Oncol Pharm Pract*. 2020 Dec;26(8):1843-1849. doi: 10.1177/1078155220905009. Epub 2020 Feb 19. PubMed PMID: 32075508.  
Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author
14. Salgado TM, Quinn CS\*, Krumbach EK\*, Wenceslao I, Gonzalez M, Reed HL\*, Syverson JG\*, Etz RS, Vangipuram K\*, Baker MR, Henry NL, Farris KB, **Hertz DL**. [Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study](#). *Support Care Cancer*. 2020 Sep;28(9):4163-4172. doi: 10.1007/s00520-019-05254-6. Epub 2020 Jan 2. PubMed PMID: 31897779.  
Role: Conceptualization, Critical Review
15. Marcath LA^, Kidwell KM, Vangipuram K\*, Gersch CL, Rae JM, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Smith EML, Henry NL, Beutler AS, **Hertz DL**. [Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy](#). *Br J Clin Pharmacol*. 2020 May;86(5):880-890. doi: 10.1111/bcp.14192. Epub 2020 Feb 4. PubMed PMID: 31823378; PubMed Central PMCID: PMC7163383.  
Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author
16. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, **Hertz DL**, Guchelaar HJ, Gaedigk A. [Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group](#). *Clin Transl Sci*. 2020 Jan;13(1):116-124. doi: 10.1111/cts.12692. Epub 2019 Oct 24. PubMed PMID: 31647186; PubMed Central PMCID: PMC6951851.  
Role: Analysis, Writing, Critical Review
17. Pasternak AL^, Kidwell KM, Dempsey JM\*, Gersch CL, Pesch A, Sun Y^, Rae JM, **Hertz DL**, Park JM [Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant](#). *Pharmacogenomics*. 2019 Apr;20(6):421-432. doi: 10.2217/pgs-2019-0002. Epub 2019 Apr 15. PubMed PMID: 30983501.  
Role: Analysis Design, Critical Review
18. Dempsey JM\*, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, **Hertz DL**. [Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole](#). *Pharmacogenomics*. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020. PubMed PMID: 31190621; PubMed Central PMCID: PMC6891932. Role: Conceptualization, Analysis Design, Writing, Critical Review, Corresponding Author
19. Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, **Hertz DL**. [Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17\\*2 gene deletion](#). *Breast Cancer Res Treat*. 2019 Jun;175(2):297-303. doi: 10.1007/s10549-019-05158-3. Epub 2019 Feb 12. PubMed PMID: 30747308; PubMed Central PMCID: PMC6534458.  
Role: Analysis Design, Writing, Critical Review
20. Marcath LA^, Coe TD, Hoylman EK, Redman BG, **Hertz DL**. [Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials](#). *BMC Cancer* 2018 Nov 22;18(1):1155. doi: 10.1186/s12885-018-5076-0.  
Role: Conceptualization, Critical Review, Corresponding Author

21. Marcath LA<sup>^</sup>, Kidwell KM, Robinson A, Vangipuram K, Burness ML, Griggs JJ, Van Poznak CV, Schott AF, Hayes DF, Henry NL, **Hertz DL**. [Patients carrying CYP2C8\\*3 have shorter systemic paclitaxel exposure](#). Pharmacogenomics. 2019 Jan;20(2):95-104. doi: 10.2217/pgs-2018-0162. Epub 2018 Dec 6. PMID: 30520341  
Role: Conceptualization, Critical Review, Corresponding Author
22. Sun Y<sup>^</sup>, Kim JH, Vangipuram K\*, Hayes DF, Lavoie Smith EM, Yeomans L, Henry NL, Stringer KA, **Hertz DL**. [Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy](#). Breast Cancer Res Treat. 2018 Oct;171(3):657-666. doi: 10.1007/s10549-018-4862-3. Epub 2018 Jun 26. PubMed PMID: 29946863; PubMed Central PMCID: PMC6119501.  
Role: Conceptualization, Critical Review, Corresponding Author
23. **Hertz DL**, Glatz A\*, Pasternak AL<sup>^</sup>, Lonigro RJ, Vats P, Wu YM, Anderson B, Rabban E, Mora E, Frank K, Robinson DR, Mody RJ, Chinnaiyan AM. [Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program](#). JCO Precis Oncol. 2018;2. doi: 10.1200/po.18.00011. Epub 2018 Jul 23. PubMed PMID: 32832831; PubMed Central PMCID: PMC7434089.  
Role: Conceptualization, Analysis Design, Analysis, Writing, Corresponding Author
24. Marcath LA<sup>^</sup>, Xi J, Hoylman EK, Kidwell KM, Kraft SL, **Hertz DL**. [Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics](#). J Oncol Pract. 2018 Jun;14(6):e368-e374. doi: 10.1200/JOP.18.00086. Epub 2018 May 22. PubMed PMID: 29787332.  
Role: Conceptualization, Critical Review, Corresponding Author
25. **Hertz DL**, Kidwell KM, Vangipuram K\*, Li F, Pai MP, Burness ML, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Smith EM, Henry NL. [Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy](#). Clin Cancer Res. 2018 Aug 1;24(15):3602-3610. doi: 10.1158/1078-0432.CCR-18-0656. Epub 2018 Apr 27. PubMed PMID: 29703818; PubMed Central PMCID: PMC6386454.  
Role: Conceptualization, Analysis Design, Writing, Corresponding Author
26. Dempsey JM\*, Xi J, Henry NL, Rae JM, **Hertz DL**. [Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer](#). Physiol Genomics. 2018 Feb 1;50(2):98-99. doi: 10.1152/physiolgenomics.00085.2017. Epub 2017 Dec 8. PubMed PMID: 29212847; PubMed Central PMCID: PMC5867615.  
Role: Conceptualization, Analysis Design, Critical Review, Corresponding Author
27. **Hertz DL**, Siden R, Modlin J, Gabel LL, Wong SF. [Drug interaction screening in SWOG clinical trials](#). Am J Health Syst Pharm. 2018 May 15;75(10):607-612. doi: 10.2146/ajhp170449. PubMed PMID: 29748299.  
Role: Conceptualization, Analysis Design, Analysis, Writing, Corresponding Author
28. Marcath LA\*, Deal AM, Van Wieren E\*, Danko W\*, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin Jr. WJ, **Hertz DL**. [Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment](#). Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311. PubMed PMID: 28877533; PubMed Central PMCID: PMC5659294.  
Role: Conceptualization, Critical Review, Corresponding Author
29. **Hertz DL**, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM. [CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study](#). Breast Cancer Res Treat. 2017 Nov;166(1):277-287. doi: 10.1007/s10549-017-4400-8. Epub 2017 Jul 20. PubMed PMID: 28730340; PubMed Central PMCID: PMC6028015.  
Role: Design, Analysis Design, Writing, Corresponding Author
30. **Hertz DL**, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. [Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients](#). Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi:

10.1007/s10549-017-4346-x. Epub 2017 Jun 22. PubMed PMID: 28643023; PubMed Central PMCID: PMC5709190.

Role: Conceptualization, Analysis Design, Writing, Corresponding Author

31. Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton R, Vaughn DJ, Beard C, Fung C, Fossa SD, **Hertz DL**, Mushiroda T, Kubo M, Einhorn LH, Cox N, Travis L. [Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer](#). Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13. PubMed PMID: 28611204; PubMed Central PMCID: PMC5626588.  
Role: Critical Review
32. Ahern TP, **Hertz DL**, Damkier P, Ejlersen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. [Cytochrome P-450 2D6 \(CYP2D6\) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity](#). Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. PubMed PMID: 27988492; PubMed Central PMCID: PMC5253974.  
Role: Critical Review
33. Robarge JD, Desta Z, Nguyen AT, Li L, **Hertz D**, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL. [Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer](#). Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9. PubMed PMID: 27943008; PubMed Central PMCID: PMC5429096.  
Role: Critical Review
34. **Hertz DL**, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Klee CG, Stearns V, Hayes DF, Skaar TC, Rae JM. [ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors](#). Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19. PubMed PMID: 27542969; PubMed Central PMCID: PMC5111879.  
Role: Analysis Design, Writing, Corresponding Author
35. **Hertz DL**, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. [Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226](#). Br J Clin Pharmacol. 2016 Jun;81(6):1134-41. doi: 10.1111/bcp.12904. Epub 2016 Apr 8. PubMed PMID: 26859101; PubMed Central PMCID: PMC4876171.  
Role: Writing, Corresponding Author
36. **Hertz DL**, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens ST, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. [Pharmacogenetic Discovery in CALGB \(Alliance\) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy](#). Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. doi: 10.1158/1078-0432.CCR-15-2823. Epub 2016 May 3. PubMed PMID: 27143689; PubMed Central PMCID: PMC5050068.  
Role: Conceptualization, Analysis Design, Writing
37. **Hertz DL**, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. [Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer](#). Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23. PubMed PMID: 27549341; PubMed Central PMCID: PMC5323433.  
Role: Conceptualization, Analysis Design, Writing, Corresponding Author
38. **Hertz DL**, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin Jr. WJ [Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity](#)

[Normalizes Endoxifen Concentrations Without Increasing Toxicity](#). *Oncologist*. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25. PubMed PMID: 27226358; PubMed Central PMCID: PMC4943390.

Role: Analysis Design, Writing

39. **Hertz DL**, Caram MV, Kidwell KM, Thibert JN, Gersch CL, Seewald NJ, Smerage J, Rubenfire M, Henry NL, Cooney KA, Leja M, Griggs JJ, Rae JM. [Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines](#). *Pharmacogenomics*. 2016 Feb;17(3):231-40. doi: 10.2217/pgs.15.162. Epub 2016 Jan 22. PubMed PMID: 26799497; PubMed Central PMCID: PMC5558515.  
Role: Analysis Design, Writing, Corresponding Author
40. **Hertz DL**, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM. [Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded \(FFPE\) breast tumor and whole blood for pharmacogenetic analyses](#). *Molecular Oncology* 2015 Nov;9(9):1868-76. doi: 10.1016/j.molonc.2015.07.002. Epub 2015 Jul 29. PMID: 26276228 PMCID: PMC4624024  
Role: Analysis Design, Writing, Corresponding Author
41. Caram ME, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, Van Poznak C, Cooney KA, **Hertz DL**, Banerjee M, Griggs JJ. [Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer](#). *Breast Cancer Res Treat*. 2015 Jul;152(1):163-172. doi: 10.1007/s10549-015-3454-8. Epub 2015 Jun 7. PubMed PMID: 26050157.  
Role: Critical Review
42. **Hertz DL**, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvinn Jr. WJ, [In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles](#). *Br J Clin Pharmacol*. 2015 Nov;80(5):1122-30. doi: 10.1111/bcp.12665. PMID: 25907378 PMCID: PMC4631184  
Role: Conceptualization, Analysis Design, Writing, Corresponding Author
43. Patel JN, Jiang C, **Hertz DL**, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. [Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B \(CALGB\) 90401 \(Alliance\)](#). *Cancer* 2014 Nov 21 doi: 10.1002/cncr.29169. PMID: 25417775 PMCID: PMC4368497  
Role: Critical Review
44. **Hertz DL**, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL, [Genetic heterogeneity beyond CYP2C8\\*3 does not explain differential sensitivity to paclitaxel-induced neuropathy](#). *Breast Cancer Res Treat* 2014;145(1):245-54. PMID: 24706167, PMCID: PMC4256153  
Role: Conceptualization, Analysis Design, Writing, Corresponding Author
45. McWhinney-Glass S\*, Winham SJ\*, **Hertz DL**, Yen-Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, and McLeod HL, [Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity](#). *Clin Cancer Res* 2013 Oct 15;19(20):5769-76 doi:10.1158/1078-0432.CCR-13.0774 PMID: 23963862, PMCID: PMC3798385  
Role: Critical Review
46. **Hertz DL**, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. [CYP2C8\\*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel](#). *Ann Oncol*. 2013 Jun;24(6):1472-8. PMID: 23413280, PMCID: PMC3660078  
Role: Conceptualization, Analysis Design, Writing, Corresponding Author
47. **Hertz DL**, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. [CYP2C8\\*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel](#). *Breast Cancer Res Treat*. 2012 Jul;134(1):401-10. PMID: 22527101, PMCID: PMC3727245  
Role: Analysis Design, Writing, Corresponding Author

48. **Hertz DL**, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC. [Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure](#). Br J Clin Pharmacol. 2012 Jul;74(1):197-200. PMID: 22680343, PMCID: PMC3394145  
Role: Analysis Design, Writing, Corresponding Author

#### PEER-REVIEWED REVIEW ARTICLES:

49. **Hertz DL**, Arwood MJ, Stocco G, Singh S, Karnes JH, Ramsey LB. [Planning and Conducting a Pharmacogenetics Association Study](#). Clin Pharmacol Ther. 2021 Apr 20;. doi: 10.1002/cpt.2270. [Epub ahead of print] PubMed PMID: 33880756.

Role: Conceptualization, Writing, Critical Review, Corresponding Author

50. Helland T<sup>^</sup>, Alsomairy S\*, Lin C\*, Søliland H, Mellgren G, **Hertz DL**. [Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer](#). J Pers Med. 2021 Mar 13;11(3). doi: 10.3390/jpm11030201. Review. PubMed PMID: 33805613; PubMed Central PMCID: PMC8000933.

Role: Conceptualization, Writing, Critical Review

51. **Hertz DL**. [Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships](#). Expert Opin Drug Metab Toxicol. 2021 Feb;17(2):227-239. doi: 10.1080/17425255.2021.1856367. Epub 2021 Jan 6. PubMed PMID: 33401943; PubMed Central PMCID: PMC7864890.

Role: Conceptualization, Writing, Corresponding Author

52. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, **Hertz DL**, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. [Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update](#). J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14. PubMed PMID: 32663120.

Role: Critical Review

53. Marcath LA<sup>^</sup>, Pasternak AL, **Hertz DL**. [Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications](#). Pharmacogenomics J. 2019 Dec;19(6):501-515. doi: 10.1038/s41397-019-0105-1. Epub 2019 Oct 15. Review. PubMed PMID: 31616046.

Role: Conceptualization, Critical Review, Corresponding Author

54. Chan A, **Hertz DL**, Morales M, Adams EJ, Gordon S Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N; D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutler AS, Peters KB, Loprinzi C, Lustberg M. [Biological predictors of chemotherapy-induced peripheral neuropathy \(CIPN\): MASCC neurological complications working group overview](#). Support Care Cancer. 2019 Oct;27(10):3729-3737. doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30. Review. PubMed PMID: 31363906; PubMed Central PMCID: PMC6728179.

Role: Writing, Critical Review

55. Pasternak AL<sup>^</sup>, Zhang L, **Hertz DL**. [CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration](#). Pharmacogenomics. 2018 Apr;19(6):563-576. doi: 10.2217/pgs-2018-0003. Epub 2018 Apr 9. PubMed PMID: 29629825.

Role: Critical Review

56. Pasternak AL<sup>^</sup>, Ward K, Luzum J, Ellingrod VL, **Hertz DL**. [Germline genetic variants with implications for disease risk and therapeutic outcomes](#). Physiological Genomics. Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Review. PubMed PMID: 28887371; PubMed Central PMCID: PMC5668651.

Role: Conceptualization, Writing, Critical Review, Corresponding Author

57. **Hertz DL**, Henry NL, Rae JM. [Germline Genetic Predictors of AI Concentrations, Estrogen Suppression and Drug Efficacy and Toxicity in Breast Cancer.](#) Pharmacogenomics. 2017 Apr;18(5):481-499. doi: 10.2217/pgs-2016-0205. Epub 2017 Mar 27. Review. PubMed PMID: 28346074; PubMed Central PMCID: PMC6219438.  
Role: Conceptualization, Analysis, Writing, Corresponding Author
58. Mora E, Smith EM, Donohoe C, **Hertz DL**. [Vincristine-induced peripheral neuropathy in pediatric cancer patients.](#) Am J Cancer Res. 2016 Nov 1;6(11):2416-2430. Review. PubMed PMID: 27904761; PubMed Central PMCID: PMC5126263.  
Role: Conceptualization, Writing, Critical Review, Corresponding Author
59. **Hertz DL**, Rae J, [Pharmacogenetics of cancer drugs.](#) (Review). Annu Rev Med 2015 Jan 14; 66:65-81. PMID: 25386932  
Role: Writing, Corresponding Author
60. **Hertz DL**, McLeod HL, [Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.](#) (Review). (CCR-13-2780R) Clin Cancer Res 2014 May 15;20(10):2530-40. doi: 10.1158/1078-0432.CCR-13-2780. PMID: 24831276  
Role: Conceptualization, Writing
61. **Hertz DL**, [Germline pharmacogenetics of paclitaxel for cancer treatment.](#) (Review). Pharmacogenomics 2013 Jul; 14(9): 1065-84. PMID: 23837481  
Role: Conceptualization, Analysis, Writing, Corresponding Author
62. **Hertz DL**, McLeod HL, [Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.](#) (Review). J Hum Genet 2013 Jun;58(6):346-52. PMID: 23677053  
Role: Writing, Corresponding Author
63. Krens SD, McLeod HL, **Hertz DL**, [Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.](#) (Review). Pharmacogenomics 2013;14(5):555-574. PMID: 23556452, PMCID: PMC3975654  
Role: Conceptualization, Critical Review, Corresponding Author
64. **Hertz DL**, McLeod HL, Irvin WJ, [Tamoxifen and CYP2D6: a contradiction of data.](#) (Review). Oncologist 2012;17(5):620-30. PMID: 22531359, PMCID: PMC3360902  
Role: Analysis, Writing

#### **EDITORIALS AND INVITED REVIEWS:**

65. **Hertz DL**, Ramsey LB, Gopalakrishnan M, Leeder JS, Van Driest SL. Mini-Review: Analysis Approaches to Identify Pharmacogenetic Associations with Pharmacodynamics. Clinical Pharmacology and Therapeutics 2021  
Role: Conceptualization, Writing, Corresponding Author
66. **Hertz DL**, Kidwell KM, Douglas JA, Viale G, Leyland-Jones B, Regan M, Rae JM. [DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses.](#) Pharmacogenomics. 2020 Aug;21(13):899-902. doi: 10.2217/pgs-2020-0071. Epub 2020 Jul 29. PubMed PMID: 32723153.  
Role: Conceptualization, Writing, Corresponding Author
67. **Hertz DL**, Sahai V. [Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity.](#) J Natl Compr Canc Netw. 2020 Apr;18(4):372-374. doi: 10.6004/jncn.2019.7527. PubMed PMID: 32259779.  
Role: Conceptualization, Writing, Corresponding Author
68. **Hertz DL**. [Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy.](#) Pharmacogenomics J. 2019 Oct;19(5):411-416. doi: 10.1038/s41397-019-0093-1. Epub 2019 Aug 9. Review. PubMed PMID: 31395959; PubMed Central PMCID: PMC6754778.  
Role: Conceptualization, Writing, Corresponding Author



69. **Hertz DL**, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, Ellingrod VL. [Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy](#). *Pharmacogenomics*. 2017 Jul 26;. doi: 10.2217/pgs-2017-0107. [Epub ahead of print] PubMed PMID: 28745551.  
Role: Conceptualization, Writing, Corresponding Author
70. **Hertz DL**, Rae JM. [Individualized Tamoxifen Dose Escalation-Response](#). *Clin Cancer Res*. 2016 Dec 15;22(24):6301. PubMed PMID: 27980025. (Invited Letter to Editor Response)  
Role: Conceptualization, Writing, Corresponding Author
71. **Hertz DL**, Rae JM. [One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity](#). *Pharmacogenomics*. 2016 Jun;17(8):823-6. doi: 10.2217/pgs-2016-0059. Epub 2016 Jun 1. PubMed PMID: 27249031. (Invited Editorial)  
Role: Conceptualization, Writing, Corresponding Author
72. **Hertz DL**, Rae JM. [Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility](#). *Clinical Cancer Research* 2016 OnlineFirst March 24, 2016; doi: 10.1158/1078-0432.CCR-16-0370 (Invited Translations Commentary)  
Role: Conceptualization, Writing, Corresponding Author
73. **Hertz DL**, McLeod HL. [Integrated patient and tumor genetic testing for individualized cancer therapy](#). *Clin Pharmacol Ther*. 2016 Feb;99(2):143-6. doi: 10.1002/cpt.294. Epub 2015 Nov 25. PubMed PMID: 26537014.  
Role: Conceptualization, Writing, Corresponding Author
74. **Hertz DL**, McLeod HL, Hoskins JM. [Pharmacogenetics of breast cancer therapies](#). (Review). *Breast* 2009 Oct;18(suppl 3):S59-63. PMID: 19914545  
Role: Analysis, Writing

#### SUBMITTED PUBLICATIONS:

75. Chen Y<sup>^^</sup>, Marcath LA<sup>^</sup>, Eliassen FM, Lende TH, Søiland H, Mellgren G, Helland T<sup>^</sup>, **Hertz DL**. Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites. *Journal of Personalized Medicine*  
Role: Conceptualization, Critical Review, Corresponding Author
76. Chen L<sup>\*</sup>, Chen CS<sup>^</sup>, Sun Y, Henry NL, Stringer KA, **Hertz DL**, Feasibility of Pharmacometabolomics to Identify Potential Predictors of Paclitaxel Pharmacokinetic Variability, *Cancer Chemotherapy and Pharmacology*  
Role: Conceptualization, Critical Review, Corresponding Author
77. **Hertz DL**, Dockter TJ, Satele DV, Loprinzi CL, Le-Rademacher J, Neuropathy Severity at the Time of Oxaliplatin Treatment Alteration in Patients with Colon Cancer (Alliance A151912). *Supportive Care in Cancer*  
Role: Conceptualization, Writing, Corresponding Author
78. **Hertz DL**, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech L, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-Centric Decision Model for Treatment Alterations in Patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). *Cancer Treatment Reviews*.  
Role: Conceptualization, Writing, Corresponding Author
79. Shakeel F<sup>^</sup>, **Hertz DL**. Prevalence of clinically relevant drug-drug interactions in Intensive Care Units in tertiary care hospitals in US and Pakistan. *International Journal of Clinical Pharmacology*  
Role: Critical Review, Corresponding Author

#### BOOK CHAPTERS:

80. **Hertz DL**, Rae JM, [Pharmacogenetic Predictors of Response](#). *Novel Biomarkers in the Continuum of Breast Cancer*. *Adv Exp Med Biol*. 2016;882:191-215. doi: 10.1007/978-3-319-22909-6\_8. PMID: 26987536 (Book Chapter)  
Role: Writing, Analysis

81. **Hertz DL**, Perissinotti AJ, Germline Pharmacogenetics in Oncology. Pharmacogenomics: Applications to Patient Care, Second Edition. ACCP. ISBN: 978-1-939862-09-9; 2015; (Book Chapter)  
Role: Conceptualization, Writing, Corresponding Author
82. **Hertz DL**, McLeod HL, Cancer Pharmacogenomics (Review). Encyclopedia of Molecular Cell Biology and Molecular Medicine. Published Online: April 8, 2015. DOI: 10.1002/3527600906.mcb.201500002  
Role: Analysis, Writing
83. **Hertz DL**, Ellingrod VL, Mcinnis M, Bipolar Disorder in the Cancer Patient. Psychopharmacology in Oncology and Palliative Care: A Practice Manual, Pgs 189-202 2014, Springer  
<http://www.springer.com/us/book/9783642401336> ISBN 978-3-642-40134-3 (Book Chapter)  
Role: Writing

### **PUBLISHED ABSTRACTS**

1. **Hertz DL**, Pasternak AL, Henry NL, Sahai V. Feasibility and Efficiency of Confirmatory DPYD Testing Only in Suspected Carriers Within an Institutional Genetics Data Repository. Poster presented virtually at: 2021 American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March. 12, 2021
2. **Hertz DL**, Dockter TJ, Satele DV, Le-Rademacher J, Loprinzi CL Neuropathy Severity at the Time of Oxaliplatin Treatment Alteration in Patients with Colon Cancer (A151912). ASCO Annual Meeting 2021 Presented Virtually; Abstract 12090
3. **Hertz DL**, Smith KL, Zong Y, Gersch CL, Pesch AM, Patel A\*, Lehman J, Henry NL, Kidwell KM, Rae JM, Stearns V. Association of OPG rs2073618 and aromatase inhibitor-induced musculoskeletal symptoms. 2020 San Antonio Breast Cancer Symposium®, December 9, 2020, PS5-25
4. Shakeel F<sup>^</sup>, Fang F, Kwon JW\*, Koo K\*, Pasternak AL, Henry NL, Sahai V, Kidwell KM, **Hertz DL**. Carriers of DPYD polymorphisms have increased risk of severe toxicity and related treatment modifications when receiving fluoropyrimidine chemotherapy. PGRN Annual Meeting. Oct 26, 2020
5. Helland T<sup>^</sup>, Baurley J, Fabienne FT, Mellgren G, Swen JJ, Brauch H, Gaedigk A, **Hertz DL**. Development of a CYP2D6 Percentage Activity System. PGRN Annual Meeting. Oct 26, 2020
6. Lin C\*, Helland T<sup>^</sup>, **Hertz DL**. The Impact of CYP3A4/5 Genetics and Drug Interactions on Tamoxifen and Metabolite Concentrations. PGRN Annual Meeting. Oct 26, 2020
7. Chen CS<sup>^</sup>, Kim J\*, Guntupalli H\*, Dorsch M, Callaghan B, Garg N<sup>^^</sup>, Jagsi R, Griggs JJ, Sabel M, **Hertz DL**. Initial pilot testing of a smartphone app for detection of chemotherapy-induced peripheral neuropathy. ASCO Quality Care Symposium. October 9-10, 2020. Presented Virtually; Abstract 176.
8. **Hertz DL**, Douglas JA, Kidwell KM, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Genome-wide association study of steady-state letrozole concentration in patients with breast cancer. May 29-June 2, 2020; ASCO Annual Meeting 2020 Presented Virtually; Abstract 538.
9. **Hertz DL**, Larson N, Pierpont TM, Bartlett N, Zelenetz AD, Wilson W, Leonard J, Jung SH, Riska S, Richards KL Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance). ASCO Annual Meeting 2020. Published online: ASCO Meeting Library. Abstract e13535
10. **Hertz DL**, Rutherford D, Gersch CL, Holdentrieder S, Mayer Z, Rossler M, Joerger M. EPHA5 rs7349683 is Not Associated with CIPN-Sensitivity in Lung Cancer Patients Receiving Paclitaxel TDM. Poster presented at: 2020 American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March. 19, 2020; Houston, TX

11. Helland T<sup>^</sup>, Baurley J, Thomas-Jean F, Mellgren G, Swenn JJ, Brauch H, Gaedigk A, and **Hertz DL**. Consensus CYP2D6 translation system improves explanation of tamoxifen bioactivation in analysis of 15 multi-racial cohorts. Poster presented at: 2020 American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March. 18, 2020; Houston, TX
12. Marcath LA<sup>^</sup>, Finley CM\*, Wong SF, and **Hertz DL**. Prevalence of drug-drug interactions in oncology patients enrolled in two completed SWOG clinical trials. Poster presented at: 2019 American College of Clinical Pharmacology Annual Meeting; Sept. 15, 2019; Chicago, IL
13. Jennaro T\*\*, Smith EM, Vangipuram K\*, Kidwell KM, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Henry NL, **Hertz DL**. Vitamin D Insufficiency and Risk of Paclitaxel-Induced Peripheral Neuropathy [abstract].; May 31-June 4, 2019; Chicago, IL. Published online: ASCO Meeting Library; May 15, 2019. Abstract e12027
14. Marcath LA<sup>^</sup>, Kidwell KM, Lavoie Smith EM, Vangipuram K, Gersch C, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Henry NL, Beutler AS, and **Hertz DL**. EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity [abstract].; May 31-June 4, 2019; Chicago, IL. Published online: ASCO Meeting Library; May 15, 2019. Abstract 532.
15. Marcath LA<sup>^</sup>, Coe TD, Redman BG, **Hertz DL**. Development of a drug-drug interaction screening tool for oncology clinical trial enrollment [abstract]. Sept. 28-29, 2018; Phoenix, AZ. Published online: ASCO Meeting Library; Sept. 24, 2018. Abstract 315.
16. Wang H, **Hertz DL**, Henry NL, Gobburu J, Ivaturi V. Population Pharmacokinetics of Paclitaxel in Breast Cancer Patients. 2018 American College of Clinical Pharmacology (ACCP) Annual Meeting. Bethesda, MD, September 23-25, 2018
17. Dempsey JM\*, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, **Hertz DL**. Association of a Low-Expression SLCO1B1 Polymorphism with Estrogen Concentrations Before and During Aromatase Inhibitor Treatment for Breast Cancer. General Poster Session Abs # 543, American Society of Clinical Oncology Annual Meeting, June 2, 2018
18. Marcath LA\*, Coe TD, Hoylman EK, Redman BG, and **Hertz DL**. Prevalence of clinically relevant drug-drug interactions in patients enrolled in NCTN clinical trials [abstract]. June 1-5, 2018; Chicago, IL. Published online: ASCO Meeting Library; May 16, 2018. Abstract e18819.
19. Salgado TM, Syverson JG, Reed HL, Quinn CS, Krumbach E, Farris KB, **Hertz DL**. Factors associated with under-reporting of peripheral neuropathy symptoms in women with breast cancer receiving paclitaxel. 20th International Social Pharmacy Workshop, Leuven, Belgium, July 2018.
20. Marcath LA<sup>^</sup>, Xi J, Hoylman E, Kidwell K, Kraft S, **Hertz DL**. Comparison of nine drug-drug interaction screening tools when assessing oral oncolytics. Abs P1-114. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 22, 2018.
21. Sun Y<sup>^</sup>, Mchugh C, Henry NL, Stringer KA, **Hertz DL**. Quantitative Nuclear Magnetic Resonance (1H-NMR) Pharmacometabolomics to Predict and Understand Paclitaxel-induced Neuropathy in Breast Cancer Patients. Abs P1-146. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 22, 2018.
22. Pasternak AL<sup>^</sup>, Kidwell KM, Dempsey J, Sun Y, **Hertz DL**, Park JM. The Impact of CYP3A5 Genotype on Tacrolimus Trough Concentrations Varies Between Routes of Administration. Abs P1-125. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 22, 2018.
23. **Hertz DL**, Kidwell KM, Vangipuram K\*, Sun D, Henry NL. Association of systemic paclitaxel concentrations with severity and progression of paclitaxel-induced peripheral neuropathy. General Poster Session Abs #1078, P6-11-03, San Antonio Breast Cancer Symposium, December 9, 2017

24. Krumbach E\*, Nobles B, Erickson S, Farris KB, **Hertz DL**. The Role of Patient Perceptions in Under Reporting Chemotherapy Induced Peripheral Neuropathy (CIPN). General Poster Session Abs #662, P4-11-06, San Antonio Breast Cancer Symposium, December 8, 2017
25. **Hertz DL**, Kidwell KM, Speth KA, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Is incomplete estradiol suppression during aromatase inhibitor treatment in post-menopausal patients with breast cancer due to insufficient systemic drug concentrations? General Poster Session Abs #1063, American Society of Clinical Oncology Annual Meeting, June 4, 2017
26. Marcath L\*, Deal AM, Desta Z, McLeod HL, Carey LA, Irvin Jr WJ, **Hertz DL**. The association of cytochromes P450 and transporter genetic variation with steady-state endoxifen concentration. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 16, 2017 and ASHP Midyear Clinical Meeting 2016
27. **Hertz DL**, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference. (General Poster Session Abs P6-09-11) San Antonio Breast Cancer Symposium December 10, 2016
28. **Hertz DL**, Robinson D, Lonigro R, Wu YM, Vats P, Cao C, Nobani A, Mora E, Chinnaiyan AM, Mody R. Clinically actionable pharmacogenetic variants identified during tumor genetic profiling in pediatric cancer patients. General Poster Session Abs#1583. American Society of Clinical Oncology Annual Meeting, June 6, 2016
29. Van Wieren E\*, Kidwell KM, Desta Z, McLeod HL, Carey LA, Irvin Jr WJ., **Hertz DL**. Assessment of a clinical and genetic algorithm to predict endoxifen concentration. Publication Only Abs#e12021. American Society of Clinical Oncology Annual Meeting 2016
30. Patel JN, Jiang C, Owzar K, **Hertz DL**, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Febbo PG, Kroetz DL, Carducci MA, Mahoney JF, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. A discovery analysis to identify clinical and genetic risk factors for gastrointestinal (GI) hemorrhage (HEM) in CALGB 90401 (Alliance) American Association of Clinical Research Annual Meeting April 18, 2016, New Orleans, Louisiana (Abs# 2037)
31. Nguyen H\*, Sun D, Henry NL, **Hertz DL**, Pharmacokinetic Prediction of Paclitaxel Induced Peripheral Neuropathy. (Quantitative Pharmacology Poster Session Abs 475) American Society of Clinical Pharmacology and Therapeutics March 10, 2016 and ASHP Midyear Clinical Meeting Abs 7-142 December 9, 2015
32. **Hertz DL**, Danko W\*, Deal A, Walko CM, Flockhart DA, McLeod HL, Ibrahim JG, Irvin Jr WJ. Comprehensive assessment of the effect of genetic polymorphisms in drug metabolizing enzymes and transporters on tamoxifen activation to endoxifen. (General Poster Session Abs P5-12-06) San Antonio Breast Cancer Symposium December 11, 2015
33. **Hertz DL**, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. CYP3A4\*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients (General Poster Session P5-12-05) San Antonio Breast Cancer Symposium December 11, 2015
34. Ahern TP, **Hertz DL**, Damkier P, Ejlersen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: an evaluation of the importance of loss-of-heterozygosity. (General Poster Session Abs P3-07-23) San Antonio Breast Cancer Symposium December 10, 2015.
35. Kidwell KM, **Hertz DL**, Leyland-Jones B, Regan MM, Dowsett M, Rae JM. Analysis of the International tamoxifen pharmacogenomics consortium (ITPC) dataset shows that genotyping DNA derived from tumor does not introduce CYP2D6 genotyping error or mask an association with tamoxifen efficacy. (General Poster Session Abs P6-09-02) San Antonio Breast Cancer Symposium December 10, 2015.

36. **Hertz DL**, Kidwell KM, Thibert JN, Gersch CL, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak C, Rae JM. Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses. General Poster Session #352. 2015 American Society of Clinical Oncology Annual Meeting, June 1, 2015
37. **Hertz DL**, Snaveley AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Rubin P, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Desta Z, Flockhart DA, Carey LA, Irvin WJ. CYP2D6 Intermediate metabolizers includes patient groups with distinct metabolic activity (General Poster Session, Abs P1-03-02) San Antonio Breast Cancer Symposium Dec 10, 2014.
38. **Hertz DL**, Jiang C, Owzar K, Halabi S, Kelly WK, Mulkey FA, Patel JN, Carducci MA, Kelley MJ, Stadler WM, Mohamed M, Morris MJ, Nakamura Y, Zembutsu H, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). General Poster Session #9612. 2014 American Society of Clinical Oncology Annual Meeting, June 1, 2014
39. **Hertz DL**, Snaveley A, Evans JP, Ibrahim JG, Anderson S, Friedman K, Weck KE, Rubin P, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Scharz G, Peppercorn JM, Graham ML, Canale ST, McLeod HL, Carey LA, Irvin Jr WJ, Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity? General Poster Session #561. 2014 American Society of Clinical Oncology Annual Meeting, June 2, 2014
40. Patel JN, Jiang C, **Hertz DL**, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). Publication only #e16061. American Society of Clinical Oncology 2014 Annual Meeting
41. Patel JN, Jiang C, **Hertz DL**, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). General Poster Session Abstract #3841. American Association of Clinical Research April 8, 2014.
42. **Hertz DL**, Owzar K, Halabi S, Kelly WK, Zembutsu H, Jiang C, Patel NJ, Watson D, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Small EJ, Febbo PG, Nakamura Y, Kubo M, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (ALLIANCE). J Clin oncol 31, 2013 (suppl; abstr 11053) General Poster Session, Tumor Biology, American Society of Clinical Oncology, June 3, 2013
43. **Hertz DL**, Dees EC, Roy S, Motsinger-Reif AA, Drobish A, McLeod HL, Carey LA. Patients Carrying CYP2C8\*3 are at Increased Risk of Paclitaxel-Induced Neuropathy (Poster Discussion: PD 10-07) San Antonio Breast Cancer Symposium Dec 7, 2012
44. **Hertz DL**, Crona D, Talameh J, Brantley S, Roode L, Theken K, Zafir B, Hull JH. Integration of Scientific Writing into an Applied Biostatistics and SAS Programming Course for Pharmaceutical Sciences Graduate Students (Poster: P0-11, Manuscript: <http://analytics.ncsu.edu/sesug/2012/PO-11.pdf>) South East SAS Users Group 2012 Conference Oct 14, 2012
45. **Hertz DL**, Dees EC, Motsinger-Reif AA, Drobish A, Roy S, McLeod HL, Carey LA. Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment. J Clin Oncol 30, 2012 (suppl; abstr 10515) Poster Discussion, American Society of Clinical Oncology, June 5, 2012
46. **Hertz DL**, Dees EC, Motsinger-Reif AA, Drobish A, Winham S, McLeod HL, Carey LA. Breast Cancer Patients Carrying the CYP2C8\*3 Variant are More Likely to Achieve Clinical Complete Response from Neoadjuvant Paclitaxel Treatment (Poster Discussion: PD 07-10) San Antonio Breast Cancer Symposium Dec 11, 2010

\*Denotes PharmD Investigations Student

\*\*Denotes PhD Student

^Denotes Post-Doctoral Fellow

^^Denotes undergraduate or BSPS Student

## **RESEARCH FUNDING**

### **ACTIVE**

XXXXXXXX (PI: Daniel L Hertz) 7/1/2021-6/30/2025  
American Cancer Society Research Scholars Grant \$761,245  
Nutrient Insufficiency and Peripheral Neuropathy Risk  
Validate vitamin D and histidine insufficiency as predictors of paclitaxel-induced peripheral neuropathy in SWOG 0221  
Role: Principal Investigator (20% effort)

N018819 (PI: James M. Rae) 10/1/2020-9/30/2021  
Breast Cancer Research Foundation \$250,000  
Title of Project: Pharmacogenomic Predictors of Breast Cancer Endocrine Response  
The major goals of this project are to discover pharmacogenomic predictors of breast cancer patient's response to and toxicity from endocrine therapy.  
Role: Co-investigator (9% effort)

XXXXXXXX (PI: Daniel L Hertz) 7/1/2019-6/30/20  
MICHR Pathway to Independence \$75,000  
Development of a Mobile App to Monitor Chemotherapy-Induced Neuropathy  
The major goals of this project are to continue development of our neuropathy detection app and test whether it detects neuropathy in a study of patients undergoing neurotoxic chemotherapy.  
Role: PI (8% effort)

XXXXXXXX (PI: Daniel L Hertz) 1/1/2020-12/31/2020  
HOPE Foundation SEED Grant \$50,000  
*Prospective Drug-Drug Interaction Screening in SWOG Clinical Trials*  
Determine whether implementation of a drug-drug interaction screening tool improves effectiveness and efficiency of screening in patients enrolling in oncology clinical trials.  
Role: PI (0% effort)

### **PENDING**

### **COMPLETED**

N018819 (PI: Amy Pasternak) 1/1/2019-12/31/2019  
AACP New Investigator Award \$50,000  
Title of Project: Defining the pharmacogenetic associations for CYP3A5 and IV tacrolimus  
The major goals of this project are to understand the pharmacogenomic relationship between CYP3A5 polymorphisms and steady state tacrolimus concentrations in patients receiving IV treatment.  
Role: Mentor (0% effort)

No Number Assigned (PI: Daniel L Hertz) 5/1/2019-4/30/2020  
Disarm Therapeutics \$20,000  
Title of Project: NFL as a plasma biomarker of chemotherapy-induced peripheral neuropathy  
The major goal of this project is to test whether plasma NFL is an objective, measurable indicator of the severity of neuropathy in patients receiving paclitaxel treatment.  
Role: Co-investigator (3% effort)

XXXXXXXX (PI: Daniel L Hertz) 7/1/2016-6/30/2017  
MICHR Pilot \$50,000

Title of Project: Genetic and Kinetic Predictors of Ineffective Estradiol Depletion During Aromatase Inhibitor Treatment

The major goals of this project are to discover kinetic and genetic predictors of ineffective estradiol depletion during aromatase inhibitor (exemestane and letrozole) treatment in patients with estrogen-receptor positive breast cancer.

Role: PI (5% effort)

No Number (PI: Daniel L Hertz) 3/1/2016-2/28/2017

Hope Foundation \$50,000

Title of Project: Kinetic and genetic predictors of estradiol depletion in SWOG0226

The major goals of this project are to discover kinetic and genetic predictors of ineffective estradiol depletion during aromatase inhibitor (anastrozole) treatment in patients with estrogen-receptor positive breast cancer.

Role: PI (no effort)

U050294 (PI: Daniel L Hertz) 12/1/2015-11/30/2016

MICHR SEED \$5,000

Title of Project: Frequency and Causes of Patient Underreporting of Peripheral Neuropathy

The major goals of this project are to document the discrepancy between patient-reported and clinician documented peripheral neuropathy and to identify patient-specific attitudes and beliefs that are associated with non-disclosure of neuropathy during paclitaxel treatment.

Role: PI (no effort)

N018819 (PI: James M. Rae) 10/1/2015-9/30/2020

Breast Cancer Research Foundation \$250,000 (annual)

Title of Project: Pharmacogenomic Predictors of Breast Cancer Endocrine Response

The major goals of this project are to discover pharmacogenomic predictors of breast cancer patient's response to and toxicity from endocrine therapy.

Role: Co-investigator (9% effort)

5KL2RR024987 (PI: Thomas P. Shanley) 6/1/2015-5/31/2017

MICHR KL2 Career Development Award (Awarded to Daniel L Hertz) \$210,665

Title of Project: Identification of neuropathy predictors for individualized paclitaxel treatment

The major goals of this project are to define the association between cumulative paclitaxel exposure and neuropathy development to assist in development of tools for personalized dosing and to provide mentored experiential training to the PI.

Role: Awardee (75% effort)

No Number Assigned 1/1/2016-12/31/2016

AACP New Investigator Award \$10,000

Title of Project: Identification of pharmacogenetic predictors of endocrine treatment for breast cancer

The major goals of this project are to discover the genetic variants responsible for determining concentrations of anastrozole and fulvestrant in post-menopausal patients with metastatic estrogen-receptor positive metastatic breast cancer.

Role: PI (0% effort)

No Number Assigned (PI: Yang, Zhang) 1/1/16-12/31/17

University of Michigan MCubed \$60,000

Understanding personalized chemotherapy-induced neuropathy by virtual GPCR screening and clinical evaluation

Role: Co-Investigator

## **INVITED PRESENTATIONS**

### **NATIONAL**

## 2021

Personalizing Supportive Care Through Genomics. Discussant Symptoms and Survivorship Oral Abstract Session. ASCO Annual Meeting 2021 Presented Virtually. Friday June 4, 2021

Efficient Implementation of DPYD Testing Using an Institutional Genetics Data Repository. Genetics Virtual Week. April 20, 2021

Predictors of Paclitaxel-induced Peripheral Neuropathy in Patients with Breast Cancer. Toxic Neuropathy Consortium. March 25, 2021

Evidence Supporting Pre-treatment DPYD Testing. Precision Medicine Leadership Summit, March 2, 2021

Treatment Alteration due to Chemotherapy-induced Peripheral Neuropathy (CIPN). MACC Neurological Complications Study Group. February 4, 2021

## 2020

FDA Petition for Pre-treatment *DPYD* testing. Clinical Pharmacogenetics Implementation Consortium December Members Meeting, Dec 3, 2020

Predictors of Taxane-induced Peripheral Neuropathy in Patients with Cancer. VCU Translational Research in Peripheral Neuropathy Seminar. Jan 30, 2020

## 2019

Embedded Prospective PGx Substudies, Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. May 10, 2019

Drug-Drug Interaction (DDI) Screening for Oncology Clinical Trial Enrollment. Oishi Symposium, SWOG Spring 2019 Meeting, April 25, 2019

## 2018

Phenomics in Pharmacogenomics, Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. May 11, 2018

Pharmacometabolomics of Paclitaxel-induced Peripheral Neuropathy (PIP). SWOG Breast Translational Medicine Committee. April 13, 2018

## 2017

Comprehensive PGx Evaluation of Steady-State Endoxifen Concentration in Tamoxifen Treated Patients, Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. May 12, 2017

Drug Interaction Screening Tool for Clinical Trial Enrollment. SWOG Cancer Care and Delivery Committee. April 27, 2017

## 2016

Pharmacogenetics of Taxane-Induced Peripheral Neuropathy. SWOG Symptom Control and Quality of Life Committee. September 15, 2016.



Translational Studies of Anastrozole and Fulvestrant PK and PD in S0226. SWOG Breast Translational Medicine Committee. April 29, 2016

Pharmacogenetic Discovery in Cooperative Group Trials. SWOG Pharmacogenomics Committee. April 29, 2016

#### 2014

GWAS of Taxane-Induced Neuropathy in CALGB Clinical Trials. Alliance Pharmacogenetics and Population Pharmacokinetics (PPP) Committee. Nov 7, 2014

Application of Pharmacogenomics to Minimize Chemotherapy Toxicity. Education Session: Pharmacogenomics in the Era of Next Generation Sequencing. American Society of Clinical Oncology 2014 Annual Meeting

Pharmacogenetics of docetaxel toxicity in CALGB/Alliance 90401. Alliance GU Committee. May 10, 2014

#### 2013

Neutropenia Pharmacogenetics in Prostate Cancer (CALGB 90401). Alliance PPP Committee. March 13, 2013

#### 2012

Pharmacogenomics: Translation and Implementation. 31<sup>st</sup> NSGC Annual Education Conference Oct 26, 2012

Neuropathy Pharmacogenomics in Prostate Cancer (CALGB 90401). PGRN-RIKEN Collaboration Meeting Oct 4, 2012, Alliance PPP Committee Nov 15, 2012

#### **LOCAL/STATE**

#### 2021

Evidence Supporting Pre-treatment DPYD Testing. University of Michigan Kemp Cease Heme/Onc Research Conference. January 28, 2021

#### 2018

Prediction of Taxane-induced Peripheral Neuropathy. University of Michigan Hematology Oncology Research Conference, March 15, 2018

#### 2017

Identification of Neuropathy Predictors for Individualized Paclitaxel Treatment. MICHR Studio. May 18, 2017

#### 2016

Discovery of Predictors of Peripheral Neuropathy to Guide Individualized Paclitaxel Treatment. University of Michigan Breast Oncology Program Translational Medicine Forum, September 29, 2016

Discovery of Individualized Predictors of Cancer Treatment Outcomes. University of Michigan Hematology Oncology Research Conference, February 25, 2016

CYP Pharmacogenetics to Predict Breast Cancer Treatment Outcomes. University of Michigan Heme Team, February 18, 2016

#### 2015

Identification of neuropathy predictors for individualized paclitaxel treatment. University of Michigan MICHRC TSA External Advisory Board Meeting October 23, 2015

Personalizing Paclitaxel Treatment in Breast Cancer Patients. University of Michigan CanSORT Project Team Meeting April 28, 2015

### 2013

A genome-wide association study of docetaxel-induced peripheral neuropathy in CALGB 90401. University of Michigan Hematology/Oncology Research Conference, May 23, 2013

Germline Pharmacogenetics in Cancer: Recognizing the Forgotten Genome. University of Michigan/Hematology/Oncology Research Conference, May 2, 2013

Germline Genetic Predictors of Paclitaxel Efficacy and Toxicity. University of Michigan Translational Breast Cancer Symposium, April 17, 2013

Pharmacogenetic Predictors of Paclitaxel Response and Toxicity in Breast Cancer Patients. Breast Spore Meeting, Jan 22, 2013

Discovery and Validation of Pharmacogenetic Predictors of Taxane-induced Peripheral Neuropathy, Graduate Dissertation Defense, Jan 4, 2013

### 2012

Discovery and Validation of Pharmacogenetic Markers of Paclitaxel-Induced Peripheral Neuropathy. Gentriscorp, Oct 24, 2012

Pharmacogenetics of Paclitaxel-Induced Neuropathy, Perou Lab Meeting, Sept 27, 2012

Patients Carrying CYP2C8\*3 are at Increased Risk of Paclitaxel-induced Neuropathy, UNC Eshelman School of Pharmacy Graduate Program Retreat, Aug 20, 2012

### 2011

The Influence of Polymorphisms in Drug Exposure Genes on the Risk of Severe Paclitaxel-induced Neuropathy, Division of Pharmacotherapy and Experimental Therapeutics Seminar, Nov 15, 2011

### 2010

Genetic Predictors of Taxane Treatment Outcomes, Division of Pharmacotherapy and Experimental Therapeutics Seminar, March 23, 2010

### PRIOR TO 2010

Creation of a Murine Mammary Carcinoma Model to Test Metronomic Delivery of a Chemotherapeutic Agent, Ernest Mario School of Pharmacy Honors Program Symposium, April 26, 2007

Synthesis of PTPP Semi-Conducting Organic Layer for a Thin Film Transistor, IGERT Summer Undergraduate Research Fellowship Symposium, Aug 12, 2004

## **TEACHING AND MENTORING**

## UNIVERSITY OF MICHIGAN

### COLLEGE OF PHARMACY TEACHING

- 2018-PRESENT** Grant Writing I (CP801)  
Course Co-Coordinator, responsible for 3 (out of 4) PhD students in 2018 Fall semester
- Introduction to Precision Health (P217)  
Guest Lecturer, 1 unit, Precision Medicine In Oncology
- 2018-2019** CPTS Seminar (CP850)  
Course coordinator
- 2017-PRESENT** Evidence Based Medicine (P604)  
Course Coordinator, responsible for content in 2<sup>nd</sup> half of semester
- Clinical and Research Ethics (P312)  
Course Coordinator, lecturer (3 units)
- Science of Medicine (P200)  
Guest lecturer, 3 units: Precision Medicine, Personalized Medicine, and Internet of Health
- 2016-PRESENT** Pharmacotherapeutics for Primary Care 1 (Nursing P620)  
Guest lecturer, 2 units: Pharmacogenomics and Drug Interactions
- Introduction to Clinical Trials (P647)  
Co-Course Director, Responsible for Semester-long group project, Lecturer (4 units, 2016-2018)
- Introduction to Drug Development (P101)  
Guest lecturer, 1 unit: Precision Medicine: Hype or Reality?
- 2013-PRESENT** Therapeutics Problem Solving (Pharmacy 432/620)  
Guest lecturer, 2 units: Drug Interactions and Therapeutic Drug Monitoring
- 2013-PRESENT** Biopharmaceutics & Pharmacogenomics (Pharmacy 563/718)  
Guest lecturer, 3 units: Retrospective PGx Analyses and Prospective PGx Studies (2019)  
Guest lecturer, 2 units: Germline Testing in Oncology and Race/Sex in PGx (2013-2018)

### PHARM D INVESTIGATION STUDENTS:

- CLASS OF 2023** Li Chen, Jaeyoung Choi, Mary Hwang
- 2022** Courtney Van Houzen, Arti Patel, Chloe Koo, Chanel Hsiang
- 2021** Harsha Guntupalli, Ivy Kim, Christina Weiss, Judith Kim
- 2020** Colin Finley, Vineet Pradhan, Taylor Coe, Lucas Hamelink, Jung Won Kwon
- 2019** Kiran Vangipuram, Jackeline Dempsey, Kristin Soreide, Adam Robinson
- 2018** Andrew Glatz, Emily Krumbach, Emily Han (co-adviser)
- 2017** Emily Van Wieren, Holly Reed, Andrew Nobani, Lauren Marcath
- 2016** William Danko, Hugh Nguyen

### POST-DOCTORAL FELLOWS:

- 2019-PRESENT** Faisal Shakeel, Thomas Helland
- 2017-2019** Lauren Marcath
- 2016-2018** Amy Pasternak, Yihan Sun (Co-mentor)

### PHD STUDENTS:

- 2019-PRESENT** Ciao-Sin (Chelsea) Chen

**BSPS HONORS STUDENTS:**

**2019-PRESENT** Yuanhuang (Harry) Chen

**2018-2020** Yongzhen Chan

**OTHER RESEARCH MENTEES**

**2021** Jiawei Chen (MICHR Summer Research Program)

**2021** Jung Won Kwon (visiting scholar)

**2017-2021** Yan Cheng Chao (SPH PhD Student, dissertation committee)

**2019-2020** Heba Izmirlı (visiting scholar)

**2019** Arti Patel (MICHR Summer Research Program)

**2017-2018** Jaeyoung Choi, Liliana Camaj (UROP)

**2016-2018** Noemi Garg (BSPS Student)

**2014-2015** Alisha Vora (UM Undergraduate Student)

**UNIVERSITY OF NORTH CAROLINA**

**UNC ESHELMAN SCHOOL OF PHARMACY TEACHING**

**2012** Quantitative Methods in Clinical Research (DPET 831)  
Guest lecturer, Statistics in Pharmacogenetics Lecture and Recitation Activity

**2011** Science and Methods in Drug Development (DPET 841)  
Course Development Team

**2010** Super Teaching Assistant (DPET 831)  
Recitation Developer and Instructor

**RESEARCH MENTEES**

**2012** Stefanie D Krens, Visiting Scholar, University of Utrecht

**SERVICE TO THE UNIVERSITY OF MICHIGAN COLLEGE OF PHARMACY**

**2017-PRESENT** Director of Admissions, CPTS Fellowship and PhD Programs

**2016-2019** Co-chair, Oncology Reorganization Committee

**2016-2018** Member, Research Foci Committee

**2016-2018** Director, CPTS Post-Doctoral Fellowship Seminar Series

**2013-PRESENT** Member, Academic Integrity Task Force

**2013-2016** Member, PharmD Investigations Committee

**2013-2015** Member, Faculty Development Committee

Other: Faculty Mentor for 2 Pharmacy Families, PharmD Patient Counseling Competition Patient, Faculty Auction, PharmD Student Interviews, Dean Candidate Interview Dinner, Volunteer Patient for P1 Laboratory Activity, Pharmacogenomics Working Group (2014-2015), Faculty Chaperone for PharmD Student Smoking Cessation Outreach Project (2014),

**SERVICE TO THE UNIVERSITY OF MICHIGAN**

**2020-PRESENT** Faculty Senate Representative

**2018-PRESENT** General Counsels Advisory Committee (GCAC), Member

**PROFESSIONAL SERVICE**

**PROFESSIONAL SOCIETY MEMBERSHIPS**

**2020-PRESENT** MASCC Neurological Complications Working Group, Biomarkers co-lead

Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Study Design Vice Chair

**2015-PRESENT** American Society of Clinical Pharmacology and Therapeutics (ASCPT), PGx Community Programming Steering Committee Member (2017) and Chair (2018). PGx Community Vice Chair (2019), chair (2020) and past-chair (2021)

**2014-PRESENT** Affiliate Member Pharmacogenomics Research Network (PGRN), CYP2D6 Genotype-to-Phenotype Working Group Member

SWOG (Inter-group) Drug Interactions Task Force Committee Chair

**2013-PRESENT** Southwest Oncology Group (SWOG), Pharmaceutical Sciences Committee, Drug Information Subcommittee, Breast Cancer Translational Medicine Committee, Pharmacist Liaison to Cancer Control & Lung Committees (2014-2016)

Pharmacogenomics Knowledge Bank (PharmGKB)

Clinical Pharmacogenetics Implementation Consortium (CPIC)

American Society for Clinical Oncology (ASCO)

American College of Clinical Pharmacy (ACCP)

**2012-PRESENT** Alliance for Clinical Trials in Oncology, Pharmacogenomics and Population Pharmacokinetics (PPP) Committee Cadre Member

## **WORKSHOPS AT PROFESSIONAL MEETINGS**

**ASCPT 2018** Substrate-Dependent Polymorphic Effects in CYP-Mediated Drug Metabolism and Challenges for Pharmacogenetic Implementation, Session Chair. March 24, 1:15-2:45, ASCPT Annual Meeting

## **EDITORIAL AND REFEREE SERVICE**

**2015-PRESENT** Editorial Board Member, Physiological Genomics

**2019-PRESENT** Editorial Board Member, Pharmacogenomics

## **AD HOC JOURNAL REFEREE (ALPHABETICAL):**

AAPS Journal  
Acta Biochimica Polonica  
Acta Oncologica  
Annals of Oncology  
Annals of Pharmacotherapy  
BMC Cancer  
BMC Medical Genomics  
BMC Women's Health  
BMJ Supportive & Palliative Care  
Brazilian Journal of Pharmaceutical Sciences  
Breast Cancer Research and Treatment  
British Journal of Clinical Pharmacology  
Cancer  
Cancer Chemotherapy and Pharmacology  
Cancer Control: Journal of the Moffitt Cancer Center  
Cancer Epidemiology, Biomarkers, and Prevention  
Cancer Management and Research  
Cancer Treatment Reviews  
Cancers  
Clinical Breast Cancer

Clinical Cancer Research  
Clinical Pharmacokinetics  
Clinical Pharmacology & Therapeutics  
Clinical and Translational Science  
Current Drug Safety  
Dose-Response  
Drug Healthcare and Patient Safety  
Expert Review of Precision Medicine and Drug Development  
Expert Opinion On Drug Metabolism & Toxicology  
Expert Review of Neurotherapeutics  
Frontiers in Pharmacology  
Genes  
Genetics in Medicine  
Genomics  
High Throughput  
International Journal of Molecular Sciences  
Journal of Cancer Survivorship  
Journal of Clinical Medicine  
Journal of Clinical Oncology  
Journal of National Cancer Institute  
Journal of Neurological Sciences  
Journal of Oncology Pharmacy Practice  
Journal of Personalized Medicine  
Journal of Proteome Research  
JCO Precision Oncology  
Medicina  
Molecular Cancer Therapeutics  
Molecular Diagnosis and Therapy  
Molecules  
Oncotarget  
Oncotargets and Therapy  
Pharmaceutical Research  
Pharmacogenetics and Genomics  
Pharmacogenomics  
Pharmacogenomics and Personalized Medicine  
Pharmacology Research & Perspectives  
Pharmacotherapy  
PLOS One  
Scientific Reports  
Supportive Care in Cancer  
The Annals of Pharmacotherapy  
Translational Cancer Research

AD HOC GRANT REVIEW:

American Foundation of Pharmaceutical Education  
MICHR Pilot Grant Program  
Welcome Trust

AD HOC ABSTRACT REVIEW:

American Society of Clinical Pharmacology and Therapeutics 2017 Annual Meeting  
Association for Clinical and Translational Science 2018 Annual Meeting

**AWARDS AND HONORS**

- 2015** MICHR K Mentored Clinical Scientist Career Development Award
- 2013** Graduate Education Advancement Board Impact Award
- 2012** American Association of Cancer Research Scholar-In-Training
- 2011** Cancer Institute of New Jersey Young Philanthropist Award  
AFPE Pre-Doctoral Fellowship Competitive Renewal
- 2010** AFPE Pre-Doctoral Fellowship
- 2009** Excellence in Teaching/Instruction Assistance Award
- 2008** Ernest Mario School of Pharmacy Honors Program Graduate  
Cell Biology Achievement Award  
Rho Chi-AFPE First Year Graduate Scholarship
- 2007** Martin Daffner Endowed Scholarship
- 2006** New Jersey Center for Biomaterials Summer Research Fellowship  
John & Josephine Calasibetta Scholarship  
Rho Chi National Pharmacy Honor Society Inductee
- 2005** Novarits-AFPE Gateway to Research Scholarship  
Martin Daffner Endowed Scholarship  
Pharmacy Alumni Association Scholarship  
“Knight In Shining Armor” Award for Student Involvement
- 2004** Eric D. Siefert Scholarship  
IGERT-Summer Undergraduate Research Fellowship